Since May 2006, some nurses and pharmacists have been allowed to prescribe medicines that were previously only allowed to be prescribed by doctors. Non-medical prescribing has been introduced to improve patients’ access to treatment – that is, making it easier for you to get the medicines you need for your child. This page from Great Ormond Street Hospital (GOSH) explains about the process.
Promising results from a trial of a new stem-cell based therapy for a rare and debilitating skin condition have been published in the Journal of Investigative Dermatology. The therapy, involving infusions of stem cells, was found to provide pain relief and to reduce the severity of this skin condition for which no cure currently exists.
This information explains about the first phase of the assessment process to diagnose gut motility problems, and what to expect when your child comes to Great Ormond Street Hospital (GOSH) for assessment.
The aim of this guideline is to support staff in ensuring the prompt assessment, recognition and treatment of jaundice, while minimizing the risks of unintended harm such as parental anxiety, decreased breastfeeding, and unnecessary costs or treatment.
Children with severe epilepsy who do not respond to traditional drugs could be treated with vitamin B6, after the discovery of a new gene by UCL Great Ormond Street Institute of Child Health (ICH) and its clinical partner Great Ormond Street Hospital (GOSH).
Researchers from the UCL Great Ormond Street Institute of Child Health have discovered a new gene change that identifies a type of the movement disorder, muscle dystonia. This new discovery will allow doctors to more easily identify patients who can benefit from treatment so effective that it can restore the ability to walk.
This page from Great Ormond Street Hospital (GOSH) explains tracheal stenosis, how it can be treated and what to expect when your child has treatment. This page mainly concentrates on the ‘long segment’ type of tracheal stenosis and its treatment.
Landau Kleffner syndrome (LKS) is a rare epilepsy. It occurs in children usually between the ages of three and nine years and is characterised by loss of language skills and silent electrical seizures during sleep. It may be associated with convulsive seizures and additional difficulties with behaviour, social interaction, motor skills and learning. It is not usually life-threatening, but can impact greatly on quality of life unless it responds well to treatment. It occurs in approximately one child in a million. The disease is more common in boys and does not usually run in families.